Mr. Hampson has focused his career primarily on the development of first generation products and related manufacturing processes for the medical and biotechnology markets. He brings an extensive background and broad knowledge of many technical disciplines, including control systems, process automation, software, fluid systems, cell culture processes, aseptic/closed-system processing, and single-use disposable systems. Prior to joining PCT, Mr. Hampson worked for two decades with Aastrom Biosciences in Ann Arbor, Michigan, where he held several positions, the most recent being Senior Engineering Fellow, an executive level engineering position tasked with providing strategic technical leadership to cell therapy manufacturing technology. He previously held the positions of Vice President Product Development; Senior Director, Product Engineering; and Director, Instrumentation Development. He is a thought leader in the application of engineering principles and innovation to the needs of bioreactor systems and the manufacture of cell therapy products, and he was the chief architect for the pioneering patient-specific automation efforts which resulted in the Aastrom Replicell System. He received his Master of Engineering, Electrical and Bachelor of Science, Electrical Engineering from Cornell University.

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards development of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem         Eric Powers         Manager of Communications and Marketing         Phone: +1-212-584-4173         Email:

NeoStem Inc. Logo

If you liked this article you might like

Neostem (NBS) Stock Declines After Pricing Secondary Public Offering

3 Breakout Stocks Under $10 for Your Trading Radar

Insider Trading Alert - UGI, NBS And MACK Traded By Insiders

Neostem (NBS): Today's Weak On High Volume Stock

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data